Advertisement

Vitamin D and Infectious Diseases

  • Christian Wejse
  • Cecilie Blenstrup Patsche
Chapter
Part of the Contemporary Endocrinology book series (COE)

Abstract

Since the eighteenth century, Vitamin D-rich adjuvant therapy has been used to treat conditions, which are nowadays considered infections. The infectious disease most frequently associated with Vitamin D is tuberculosis, and early scientific studies from the nineteenth century reported on the use of cod liver oil treatment, which remained an important part of tuberculosis treatment as late as in 1960. Vitamin D plays an independent modulatory role in the immune response toward infections, and infectious diseases have been associated with Vitamin D deficiency. Vitamin D deficiency is believed to be both a risk marker and a contributor to infectious diseases, and in recent years the association between infectious diseases, Vitamin D levels, and the use of Vitamin D adjuvant therapy have been widely examined for a number of infections. This chapter will explore these associations for tuberculosis, other respiratory tract infections, sepsis, HIV, and hepatitis.

Keywords

Tuberculosis Respiratory tract infection Sepsis Human immunodeficiency virus Hepatitis C Infectious diseases Vitamin D deficiency 

References

  1. 1.
    Provvedini DM, Tsoukas CD, Deftos LJ, Manolagas SC. 1,25-dihydroxyvitamin D3 receptors in human leukocytes. Science. 1983;221(4616):1181–3.PubMedCrossRefGoogle Scholar
  2. 2.
    Hayes CE, Nashold FE, Spach KM, Pedersen LB. The immunological functions of the vitamin D endocrine system. Cell Mol Biol (Noisy-Le-Grand). 2003;49(2):277–300.Google Scholar
  3. 3.
    Liu PT, Stenger S, Li H, Wenzel L, Tan BH, Krutzik SR, et al. Toll-like receptor triggering of a vitamin D-mediated human antimicrobial response. Science. 2006;311(5768):1770–3.PubMedCrossRefGoogle Scholar
  4. 4.
    Zasloff M. Fighting infections with vitamin D. Nat Med. 2006;12(4):388–90.PubMedCrossRefGoogle Scholar
  5. 5.
    Korf H, Decallonne B, Mathieu C. Vitamin D for infections. Curr Opin Endocrinol Diabetes Obes. 2014;21(6):431–6.PubMedCrossRefGoogle Scholar
  6. 6.
    Holtz F, Frohberg H. Role of the calcinosis factor (vitamin D, dihydrotachysterin) in therapy of tuberculosis. Beitr Klin Tuberk Spezif Tuberkuloseforsch. 1957;117(2):265–75.PubMedCrossRefGoogle Scholar
  7. 7.
    Grad R. Cod and the consumptive: a brief history of cod-liver oil in the treatment of pulmonary tuberculosis. Pharm Hist. 2004;46(3):106–20.PubMedGoogle Scholar
  8. 8.
    Bennett JH. Treatise on the oleum jecoris aselli. London: S. Highley; 1841.Google Scholar
  9. 9.
    Stillé A. Therapeutics and Materia Medica. Lond Monthly J. 1849:239.Google Scholar
  10. 10.
    Green M. Cod liver oil and tuberculosis. BMJ. 2011;343:d7505.PubMedCrossRefGoogle Scholar
  11. 11.
    Wood GB. A treatise on the practice of medicine. 4th ed. Philadelphia: Lippincott, Grambo and Co.; 1855. p. 96–7.Google Scholar
  12. 12.
    Lyngbye J. Lyssagen. Niels Finsen og hans team på Finsensinstituttet. 1st ed. Copenhagen: Gyldendal; 2003.Google Scholar
  13. 13.
    David HL, Jones WD Jr, Newman CM. Ultraviolet light inactivation and photoreactivation in the mycobacteria. Infect Immun. 1971;4(3):318–9.PubMedPubMedCentralGoogle Scholar
  14. 14.
    Riley RL, Knight M, Middlebrook G. Ultraviolet susceptibility of BCG and virulent tubercle bacilli. Am Rev Respir Dis. 1976;113(4):413–8.PubMedGoogle Scholar
  15. 15.
    van der Lugt L, Rottier PB. Finsen therapy and vitamin D. Acta Derm Venereol. 1958;38(4):264–73.Google Scholar
  16. 16.
    Moller KI, Kongshoj B, Philipsen PA, Thomsen VO, Wulf HC. How Finsen’s light cured lupus vulgaris. Photodermatol Photoimmunol Photomed. 2005;21(3):118–24.PubMedCrossRefGoogle Scholar
  17. 17.
    Charpy J. Aspects of vitamin and functional substance therapy in dermatology. Bull Med. 1950;64(24):555–9.PubMedGoogle Scholar
  18. 18.
    Dowling GB, Prosser Thomas EW. Treatment of lupus vulgaris with calciferol. Lancet. 1946;1:919–22.PubMedCrossRefGoogle Scholar
  19. 19.
    Riehl. Two years experience with vitamin D2 in the treatment of tuberculosis of the skin. Arch Klin Exp Dermatol. 1950;191:615–8.Google Scholar
  20. 20.
    Ruiter M, Groen HD. The effect of nonirradiated ergosterol in calciferol-treated tuberculosis cutis. Dermatologica. 1949;99(6):345–52.PubMedCrossRefGoogle Scholar
  21. 21.
    Gutierrez PD, Fernandez MC. Vitamin D2 in cutaneous tuberculosis; (progress report). Acta Med Philipp. 1950;7(1):55–9.PubMedGoogle Scholar
  22. 22.
    Thaler E. Treatment of tuberculosis of the skin with massive doses of vitamin D2. Med Monatsschr. 1950;4(6):452–4.PubMedGoogle Scholar
  23. 23.
    Macrae DE. The use of calciferol in tuberculous conditions. Lancet. 1947;249(6439):135–7.CrossRefGoogle Scholar
  24. 24.
    Lomholt S. Calciferol therapy of lupus vulgaris. Acta Derm Venereol. 1950;30(4):329–33.PubMedGoogle Scholar
  25. 25.
    Pogorzelski J, Miedzinski F. Six years of calciferol therapy in tuberculosis of the skin. Dermatologica. 1954;109(6):355–69.PubMedCrossRefGoogle Scholar
  26. 26.
    Ellman P, Anderson K. Calciferol in tuberculosis peritonitis with disseminated tuberculosis. BMJ. 1948;1:394.PubMedPubMedCentralCrossRefGoogle Scholar
  27. 27.
    Wallis HR. Tuberculous mesenteric adenitis in children. Br Med J. 1955;1(4906):128–33.PubMedPubMedCentralCrossRefGoogle Scholar
  28. 28.
    Gerecke W. Vitamin D2 alone and in combination with TB 1/698 in the treatment of pulmonary tuberculosis. Z Tuberk. 1950;95(3–4):182–7.PubMedGoogle Scholar
  29. 29.
    Brincourt J. Liquefying effect on suppurations of an oral dose of calciferol. Presse Med. 1969;77(13):467–70.PubMedGoogle Scholar
  30. 30.
    Ghosh PK. Vitamin D2 in tuberculosis. J Indian Med Assoc. 1957;29(3):90–3.PubMedGoogle Scholar
  31. 31.
    Trautwein H, Stein E. Vitamin D2 and pulmonary tuberculosis; effects and therapeutic results. Beitr Klin Tuberk Spezif Tuberkuloseforsch. 1952;107(4):295–313.PubMedCrossRefGoogle Scholar
  32. 32.
    Gertler W. The question of late injuries in long lasting vitamin D treatment of cutaneous tuberculosis. Z Tuberk. 1953;103(1–3):26–50.PubMedGoogle Scholar
  33. 33.
    Kalkoff KW. Chemotherapy and vitamin D therapy of skin tuberculosis. Ergeb Gesamten Tuberkuloseforsch. 1956;13:331–70.PubMedGoogle Scholar
  34. 34.
    Winterberg H. Vigantol therapy in early tuberculous infections of the lungs, and in exsudative pulmonary tuberculosis. Z Tuberk. 1950;95(3–4):146–50.PubMedGoogle Scholar
  35. 35.
    Marcussen PV. Treatment of lupus vulgaris with calciferol alone; results after five years of observation. Dan Med Bull. 1955;2(5):129–36.PubMedGoogle Scholar
  36. 36.
    Seeber F. The use of vitamin D2 in the treatment of pulmonary tuberculosis. Z Tuberk. 1950;95(3–4):151–5.PubMedGoogle Scholar
  37. 37.
    Holick MF. Resurrection of vitamin D deficiency and rickets. J Clin Invest. 2006;116(8):2062–72.PubMedPubMedCentralCrossRefGoogle Scholar
  38. 38.
    Vieth R. Vitamin D supplementation, 25-hydroxyvitamin D concentrations, and safety. Am J Clin Nutr. 1999;69(5):842–56.PubMedCrossRefGoogle Scholar
  39. 39.
    Hathcock JN, Shao A, Vieth R, Heaney R. Risk assessment for vitamin D. Am J Clin Nutr. 2007;85(1):6–18.PubMedCrossRefGoogle Scholar
  40. 40.
    Fruhwald R. Changes in the blood analysis in vitamin D2 treatment of cutaneous tuberculosis. Dtsch Gesundheitsw. 1953;8(3):67–9.PubMedGoogle Scholar
  41. 41.
    Sonne LM. Calciferol in dermatology. Ugeskr Laeger. 1952;114(4):109–13.PubMedGoogle Scholar
  42. 42.
    Dowling GB. The present status of vitamin D2 in the treatment of lupus vulgaris. Dermatologica. 1957;115(4):491–5.PubMedCrossRefGoogle Scholar
  43. 43.
    Fielding J, Maloney JJ. Calciferol, streptomycin, and para-aminosalicylic acid in pulmonary tuberculosis. Lancet. 1951;2(14):614–7.PubMedCrossRefGoogle Scholar
  44. 44.
    Jongmans LJ, Hopmans PJ, Kars HJ, Michgelsen H. Danger of reactivating tuberculous processes in the lungs with the administration of massive doses of vitamin D2. Ned Tijdschr Geneeskd. 1950;94(34):2470–3.PubMedGoogle Scholar
  45. 45.
    Grassi A. Modern therapy of cutaneous tuberculosis. Minerva Med. 1957;48(51):2269–73.PubMedGoogle Scholar
  46. 46.
    Martineau AR, Wilkinson RJ, Wilkinson KA, Newton SM, Kampmann B, Hall BM, et al. A single dose of vitamin D enhances immunity to mycobacteria. Am J Respir Crit Care Med. 2007;176(2):208–13.PubMedCrossRefGoogle Scholar
  47. 47.
    Coussens AK, Wilkinson RJ, Hanifa Y, Nikolayevskyy V, Elkington PT, Islam K, Timms PM, Venton TR, Bothamley GH, Packe GE, Darmalingam M, Davidson RN, Milburn HJ, Baker LV, Barker RD, Mein CA, Bhaw-Rosun L, Nuamah R, Young DB, Drobniewski FA, Griffiths CJ, Martineau AR. Vitamin D accelerates resolution of inflammatory responses during tuberculosis treatment. Proc Natl Acad Sci U S A. 2012;109(38):15449–54.PubMedPubMedCentralCrossRefGoogle Scholar
  48. 48.
    Wilkinson RJ, Llewelyn M, Toossi Z, Patel P, Pasvol G, Lalvani A, et al. Influence of vitamin D deficiency and vitamin D receptor polymorphisms on tuberculosis among Gujarati Asians in west London: a case-control study. Lancet. 2000;355(9204):618–21.PubMedCrossRefGoogle Scholar
  49. 49.
    Ustianowski A, Shaffer R, Collin S, Wilkinson RJ, Davidson RN. Prevalence and associations of vitamin D deficiency in foreign-born persons with tuberculosis in London. J Infect. 2005;50(5):432–7.PubMedCrossRefGoogle Scholar
  50. 50.
    Wejse C, Olesen R, Rabna P, Kaestel P, Gustafson P, Aaby P, et al. Serum 25-hydroxy-vitamin D in a West African population of tuberculosis patients and un-matched healthy controls. Am J Clin Nutr. 2007;86(5):1376–83.PubMedCrossRefGoogle Scholar
  51. 51.
    Zeng J, Wu G, Yang W, Gu X, Liang W, Yao Y, Song Y. A serum vitamin D level <25nmol/l pose high tuberculosis risk: a meta-analysis. PLoS One. 2015;10(5):e0126014.PubMedPubMedCentralCrossRefGoogle Scholar
  52. 52.
    Stead WW, Senner JW, Reddick WT, Lofgren JP. Racial differences in susceptibility to infection by Mycobacterium tuberculosis. N Engl J Med. 1990;322(7):422–7.PubMedCrossRefGoogle Scholar
  53. 53.
    Harris SS. Vitamin D and African Americans. J Nutr. 2006;136(4):1126–9.PubMedCrossRefGoogle Scholar
  54. 54.
    Bellamy R, Ruwende C, Corrah T, McAdam KP, Thursz M, Whittle HC, Hill AV. Tuberculosis and chronic hepatitis B virus infection in Africans and variation in the vitamin D receptor gene. J Infect Dis. 1999;179(3):721–4.PubMedCrossRefGoogle Scholar
  55. 55.
    Bornman L, Campbell SJ, Fielding K, Bah B, Sillah J, Gustafson P, et al. Vitamin D receptor polymorphisms and susceptibility to tuberculosis in West Africa: a case-control and family study. J Infect Dis. 2004;190(9):1631–41.PubMedCrossRefGoogle Scholar
  56. 56.
    Olesen R, Wejse C, Velez DR, Bisseye C, Sodemann M, Aaby P, et al. DC-SIGN (CD209), pentraxin 3 and vitamin D receptor gene variants associate with pulmonary tuberculosis risk in West Africans. Genes Immun. 2007;8(6):456–67.PubMedCrossRefGoogle Scholar
  57. 57.
    Roth DE, Soto G, Arenas F, Bautista CT, Ortiz J, Rodriguez R, et al. Association between vitamin D receptor gene polymorphisms and response to treatment of pulmonary tuberculosis. J Infect Dis. 2004;190(5):920–7.PubMedCrossRefGoogle Scholar
  58. 58.
    Soborg C, Andersen AB, Range N, Malenganisho W, Friis H, Magnussen P, et al. Influence of candidate susceptibility genes on tuberculosis in a high endemic region. Mol Immunol. 2007;44(9):2213–20.PubMedCrossRefGoogle Scholar
  59. 59.
    Gao L, Tao Y, Zhang L, Jin Q. Vitamin D receptor genetic polymorphisms and tuberculosis: updated systematic review and meta-analysis. Int J Tuberc Lung Dis. 2010;14(1):15–23.PubMedGoogle Scholar
  60. 60.
    Wejse C, Gomes VF, Rabna P, Gustafson P, Aaby P, Lisse I, Andersen PL, Glerup H, Sodemann M. Vitamin D as supplementary treatment for tuberculosis—a randomised double-blind placebo-controlled trial. Am J Respir Crit Care Med. 2009;179:843–50.PubMedCrossRefGoogle Scholar
  61. 61.
    Zittermann A, Pilz S, Hoffmann H, März W. Vitamin D and airway infections: a European perspective. Eur J Med Res. 2016;21:14.PubMedPubMedCentralCrossRefGoogle Scholar
  62. 62.
    Ganmaa D, Giovannucci E, Bloom BR, Fawzi W, Burr W, Batbaatar D, et al. Vitamin D, tuberculin skin test conversion, and latent tuberculosis in Mongolian school-age children: a randomized, double-blind, placebocontrolled feasibility trial. Am J Clin Nutr. 2012;96:391.PubMedPubMedCentralCrossRefGoogle Scholar
  63. 63.
    Lawn SD, Macallan DC. Hypercalcemia: a manifestation of immune reconstitution complicating tuberculosis in an HIV-infected person. Clin Infect Dis. 2004;38(1):154–5.PubMedCrossRefGoogle Scholar
  64. 64.
    Roussos A, Lagogianni I, Gonis A, Ilias I, Kazi D, Patsopoulos D, et al. Hypercalcaemia in Greek patients with tuberculosis before the initiation of anti-tuberculosis treatment. Respir Med. 2001;95(3):187–90.PubMedCrossRefGoogle Scholar
  65. 65.
    Chan TY. Symptomatic hypercalcaemia is rare in tuberculous patients in Hong Kong. Ann Trop Med Parasitol. 1996;90(6):663–4.PubMedCrossRefGoogle Scholar
  66. 66.
    Tan TT, Lee BC, Khalid BA. Low incidence of hypercalcaemia in tuberculosis in Malaysia. J Trop Med Hyg. 1993;96(6):349–51.PubMedGoogle Scholar
  67. 67.
    Kelestimur F, Guven M, Ozesmi M, Pasaoglu H. Does tuberculosis really cause hypercalcemia? J Endocrinol Invest. 1996;19(10):678–81.PubMedCrossRefGoogle Scholar
  68. 68.
    Fuss M, Karmali R, Pepersack T, Bergans A, Dierckx P, Prigogine T, et al. Are tuberculous patients at a great risk from hypercalcemia? Q J Med. 1988;69(259):869–78.PubMedGoogle Scholar
  69. 69.
    Salimpour R. Rickets in Tehran. Arch Dis Child. 1975;50:63–5.PubMedPubMedCentralCrossRefGoogle Scholar
  70. 70.
    Lubani MM, Al-Shab TS, Al-Saleh QA, et al. Vitamin-D-deficiency rickets in Kuwait: the prevalence of a preventable disease. Ann Trop Paediatr. 1989;3:134–9..PubMedCrossRefGoogle Scholar
  71. 71.
    Lawson DEM, Cole TJ, Salem SI, et al. Aetiology of rickets in Egyptian children. Hum Nutr Clin Nutr. 1987;41:199–208.PubMedGoogle Scholar
  72. 72.
    Muhe L, Lulseged S, Mason KE, Simoes EA. Case-control study of the role of nutritional rickets in the risk of developing pneumonia in Ethiopian children. Lancet. 1997;349(9068):1801–4.PubMedCrossRefGoogle Scholar
  73. 73.
    Jat KR. Vitamin D deficiency and lower respiratory tract infections in children: a systematic review and meta-analysis of observational studies. Trop Dr. 2017;47(1):77–84.Google Scholar
  74. 74.
    Ginde AA, Mansbach JM, Camargo CA Jr. Association between serum 25-hydroxyvitamin D level and upper respiratory tract infection in the Third National Health and Nutrition Examination Survey. Arch Intern Med. 2009;169(4):384–90.PubMedPubMedCentralCrossRefGoogle Scholar
  75. 75.
    Berry DJ, et al. Vitamin D status has a linear association with seasonal infections and lung function in British adults. Br J Nutr. 2011;106:1433–40.PubMedCrossRefGoogle Scholar
  76. 76.
    Laaksi I, Ruohola JP, Tuohimaa P, Auvinen A, Haataja R, Pihlajamäki H, et al. An association of serum vitamin D concentrations <40 nmol/L with acute respiratory tract infection in young Finnish men. Am J Clin Nutr. 2007;86:714.PubMedCrossRefGoogle Scholar
  77. 77.
    Jolliffe DA, Griffiths CJ, Martineau AR. Vitamin D in the prevention of acute respiratory infection: systematic review of clinical studies. J Steroid Biochem Mol Biol. 2013;136:321–9.PubMedCrossRefGoogle Scholar
  78. 78.
    Bryson KJ, Nash AA, Norval M. Does vitamin D protect against respiratory viral infections? Epidemiol Infect. 2014;142(9):1789–801.PubMedCrossRefGoogle Scholar
  79. 79.
    Manaseki-Holland S, et al. Effect on the incidence of pneumonia of vitamin D supplementation by quarterly bolus dose to infants in Kabul: a randomised controlled superiority trial. Lancet. 2012;379:1419–27.PubMedPubMedCentralCrossRefGoogle Scholar
  80. 80.
    Youssef D, Bailey B, El-Abbassi A, Vannoy M, Manning T, Moorman JP, et al. Healthcare costs of methicillin resistant Staphylococcus aureus and Pseudomonas aeruginosa infections in veterans: role of vitamin D deficiency. Eur J Clin Microbiol Infect Dis. 2012;31(3):281–6.PubMedCrossRefGoogle Scholar
  81. 81.
    Thomason J, Rentsch C, Stenehjem EA, Hidron AI, Rimland D. Association between vitamin D deficiency and methicillin-resistant Staphylococcus aureus infection. Infection. 2015;43(6):715–22.PubMedCrossRefGoogle Scholar
  82. 82.
    Matheson EM, Mainous AG III, Hueston WJ, Diaz VA, Everett CJ. Vitamin D and methicillin-resistant Staphylococcus aureus nasal carriage. Scand J Infect Dis. 2010;42(6–7):455–60.PubMedCrossRefGoogle Scholar
  83. 83.
    Watkins RR, Yamshchikov AV, Lemonovich TL, Salata RA. The role of vitamin D deficiency in sepsis and potential therapeutic implications. J Infect. 2011;63(5):321–6.PubMedCrossRefGoogle Scholar
  84. 84.
    Jeng L, Yamshchikov AV, Judd SE, Blumberg HM, Martin GS, Ziegler TR, et al. Alterations in vitamin D status and anti-microbial peptide levels in patients in the intensive care unit with sepsis. J Transl Med. 2009;7:28.PubMedPubMedCentralCrossRefGoogle Scholar
  85. 85.
    Lange N, Litonjua AA, Gibbons FK, Giovannucci E, Christopher KB. Pre-hospital vitamin D concentration, mortality, and bloodstream infection in a hospitalized patient population. Am J Med. 2013;126(7):640.e19–27.CrossRefGoogle Scholar
  86. 86.
    de Haan K, Groeneveld AB, de Geus HR, Egal M, Struijs A. Vitamin D deficiency as a risk factor for infection, sepsis and mortality in the critically ill: systematic review and meta-analysis. Crit Care. 2014;18(6):660.PubMedPubMedCentralCrossRefGoogle Scholar
  87. 87.
    Upala S, Sanguankeo A, Permpalung N. Significant association between vitamin D deficiency and sepsis: a systematic review and meta-analysis. BMC Anesthesiol. 2015;15:84.PubMedPubMedCentralCrossRefGoogle Scholar
  88. 88.
    Leaf DE, Raed A, Donnino MW, et al. Randomized controlled trial of calcitriol in severe sepsis. Am J Respir Crit Care Med. 2014;190:533–41.PubMedPubMedCentralCrossRefGoogle Scholar
  89. 89.
    Mata-Granados JM, Vargas-Vasserot J, Ferreiro-Vera C, et al. Evaluation of vitamin D endocrine system (VDES) status and response to treatment of patients in intensive care units (ICUs) using an on-line SPE-LC-MS/MS method. J Steroid Biochem Mol Biol. 2010;121:452–5.PubMedCrossRefGoogle Scholar
  90. 90.
    Amrein K, Schnedl C, Holl A, et al. Effect of high-dose vitamin D3 on hospital length of stay in critically ill patients with vitamin D deficiency: the VITdAL-ICU randomized clinical trial. JAMA. 2014;312:1520–30.PubMedCrossRefGoogle Scholar
  91. 91.
    Connor RI, Rigby WFC. 1a,25-Dihydroxyvitamin D3 inhibits productive infection of human monocytes by HIV-1. Biochem Biophys Res Commun. 1991;176(2):852–9.PubMedCrossRefGoogle Scholar
  92. 92.
    Kizaki M, Ikeda Y, Simon KJ, Nanjo M, Koeffler HP. Effect of 1,25-dihydroxyvitamin D3 and its analogs on human immunodeficiency virus infection in monocytes/macrophages. Leukemia. 1993;7(10):1525–30.PubMedGoogle Scholar
  93. 93.
    Khoo AL, Chai L, Koenen H, Joosten I, Netea M, Van Der Ven A. Translating the role of vitamin D 3 in infectious diseases. Crit Rev Microbiol. 2012;38(2):122–35.PubMedCrossRefGoogle Scholar
  94. 94.
    Villamor E. A potential role for vitamin D on HIV infection? Nutr Rev. 2006;64(5):226–33.PubMedCrossRefGoogle Scholar
  95. 95.
    Bergman P, Walter-Jallow L, Broliden K, Agerberth B, Söderlund J. The antimicrobial peptide LL-37 inhibits HIV-1 replication. Curr HIV Res. 2007;5(4):410–5.PubMedCrossRefGoogle Scholar
  96. 96.
    Lake JE, Adams JS. Vitamin D in HIV-infected patients. Curr HIV/AIDS Rep. 2011;8(3):133–41.PubMedCrossRefGoogle Scholar
  97. 97.
    Griffin AT, Arnold FW. Review of metabolic, immunologic, and virologic consequences of suboptimal vitamin D levels in HIV infection. AIDS Patient Care STDs. 2012;26(9):516–25.PubMedCrossRefGoogle Scholar
  98. 98.
    Pinzone MR, Di Rosa M, Malaguarnera M, Madeddu G, Focà E, Ceccarelli G, et al. Vitamin D deficiency in HIV infection: an underestimated and undertreated epidemic. Eur Rev Med Pharmacol Sci. 2013;17(9):1218–32.PubMedGoogle Scholar
  99. 99.
    Mansueto P, Seidita A, Vitale G, Gangemi S, Iaria C, Cascio A. Vitamin D deficiency in HIV infection: not only a bone disorder. BioMed Res Int. 2015;2015:735615.PubMedPubMedCentralCrossRefGoogle Scholar
  100. 100.
    Havers F, Smeaton L, Gupte N, Detrick B, Bollinger RC, Hakim J, et al. 25-hydroxyvitamin D insufficiency and deficiency is associated with HIV disease progression and virological failure post-antiretroviral therapy initiation in diverse multinational settings. J Infect Dis. 2014;210(2):244–53.PubMedPubMedCentralCrossRefGoogle Scholar
  101. 101.
    Shepherd L, Souberbielle JC, Bastard JP, Fellahi S, Capeau J, Reekie J, et al. Prognostic value of vitamin D level for all-cause mortality, and association with inflammatory markers, in HIV-infected persons. J Infect Dis. 2014;210(2):234–43.PubMedCrossRefGoogle Scholar
  102. 102.
    Mehta S, Giovannucci E, Mugusi FM, Spiegelman D, Aboud S, Hertzmark E, et al. Vitamin D status of HIV-infected women and its association with HIV disease progression, anemia, and mortality. PLoS One. 2010;5(1):e8770.PubMedPubMedCentralCrossRefGoogle Scholar
  103. 103.
    Terrier B, Carrat F, Geri G, Pol S, Piroth L, Halfon P, et al. Low 25-OH vitamin D serum levels correlate with severe fibrosis in HIV-HCV co-infected patients with chronic hepatitis. J Hepatol. 2011;55(4):756–61.PubMedCrossRefGoogle Scholar
  104. 104.
    Haug C, Müller F, Aukrust P, Frøland SS. Subnormal serum concentration of 1, 25-vitamin d in human immunodeficiency virus infection: correlation with degree of immune deficiency and survival. J Infect Dis. 1994;169(4):889–93.PubMedCrossRefGoogle Scholar
  105. 105.
    Dao CN, Patel P, Overton ET, Rhame F, Pals SL, Johnson C, et al. Low vitamin D among HIV-infected adults: prevalence of and risk factors for low vitamin D levels in a cohort of HIV-infected adults and comparison to prevalence among adults in the us general population. Clin Infect Dis. 2011;52(3):396–405.PubMedCrossRefGoogle Scholar
  106. 106.
    Brown TT, McComsey GA. Association between initiation of antiretroviral therapy with efavirenz and decreases in 25-hydroxyvitamin D. Antivir Ther. 2010;15(3):425–9.PubMedCrossRefGoogle Scholar
  107. 107.
    Mueller NJ, Fux CA, Ledergerber B, Elzi L, Schmid P, Dang T, et al. High prevalence of severe vitamin D deficiency in combined antiretroviral therapy-naive and successfully treated Swiss HIV patients. AIDS. 2010;24(8):1127–34.PubMedCrossRefGoogle Scholar
  108. 108.
    Welz T, Childs K, Ibrahim F, Poulton M, Taylor CB, Moniz CF, et al. Efavirenz is associated with severe vitamin D deficiency and increased alkaline phosphatase. AIDS. 2010;24(12):1923–8.PubMedCrossRefGoogle Scholar
  109. 109.
    Fox J, Peters B, Prakash M, Arribas J, Hill A, Moecklinghoff C. Improvement in vitamin D deficiency following antiretroviral regime change: results from the MONET trial. AIDS Res Hum Retrovir. 2011;27(1):29–34.PubMedCrossRefGoogle Scholar
  110. 110.
    Conesa-Botella A, Florence E, Lynen L, Colebunders R, Menten J, Moreno-Reyes R. Decrease of vitamin D concentration in patients with HIV infection on a non nucleoside reverse transcriptase inhibitor-containing regimen. AIDS Res Ther. 2010;7:40.PubMedPubMedCentralCrossRefGoogle Scholar
  111. 111.
    Cozzolino M, Vidal M, Arcidiacono MV, Tebas P, Yarasheski KE, Dusso AS. HIV-protease inhibitors impair vitamin D bioactivation to 1,25-dihydroxyvitamin D. AIDS. 2003;17(4):513–20.PubMedCrossRefGoogle Scholar
  112. 112.
    Cervero M, Agud JL, Torres R, García-Lacalle C, Alcázar V, Jusdado JJ, et al. Higher vitamin D levels in HIV-infected out-patients on treatment with boosted protease inhibitor monotherapy. HIV Med. 2013;14(9):556–62.PubMedCrossRefGoogle Scholar
  113. 113.
    Lang PO, Samaras N, Samaras D, Aspinall R. How important is vitamin D in preventing infections? Osteoporos Int. 2013;24(5):1537–53.PubMedCrossRefGoogle Scholar
  114. 114.
    Kakalia S, Sochett EB, Stephens D, Assor E, Read SE, Bitnun A. Vitamin D supplementation and CD4 count in children infected with human immunodeficiency virus. J Pediatr. 2011;159(6):951–7.PubMedCrossRefGoogle Scholar
  115. 115.
    Arpadi SM, McMahon D, Abrams EJ, Bamji M, Purswani M, Engelson ES, et al. Effect of bimonthly supplementation with oral cholecalciferol on serum 25-hydroxyvitamin D concentrations in HIV-infected children and adolescents. Pediatrics. 2009;123(1):e121.PubMedPubMedCentralCrossRefGoogle Scholar
  116. 116.
    Giacomet V, Vigano A, Manfredini V, Cerini C, Bedogni G, Mora S, et al. Cholecalciferol supplementation in HIV-infected youth with vitamin d insufficiency: effects on vitamin D status and T-cell phenotype: a randomized controlled trial. HIV Clin Trials. 2013;14(2):51–60.PubMedCrossRefGoogle Scholar
  117. 117.
    Havens PL, Mulligan K, Hazra R, Flynn P, Rutledge B, Van Loan MD, et al. Serum 25-hydroxyvitamin D response to vitamin D3 supplementation 50,000 IU monthly in youth with HIV-1 infection. J Clin Endocrinol Metab. 2012;97(11):4004–13.PubMedPubMedCentralCrossRefGoogle Scholar
  118. 118.
    Cholongitas E, Theocharidou E, Goulis J, Tsochatzis E, Akriviadis E, Burroughs K. Review article: the extra-skeletal effects of vitamin D in chronic hepatitis C infection. Aliment Pharmacol Ther. 2012;35(6):634–46.PubMedCrossRefGoogle Scholar
  119. 119.
    Clark PJ, Thompson AJ, Vock DM, Kratz LE, Tolun AA, Muir AJ, et al. Hepatitis C virus selectively perturbs the distal cholesterol synthesis pathway in a genotype-specific manner. Hepatology. 2012;56(1):49–56.PubMedCrossRefGoogle Scholar
  120. 120.
    Masuda S, Okano T, Osawa K, Shinjo M, Suematsu T, Kobayashi T. Concentrations of vitamin D-binding protein and vitamin D metabolites in plasma of patients with liver cirrhosis. J Nutr Sci Vitaminol. 1989;35(4):225–34.PubMedCrossRefGoogle Scholar
  121. 121.
    Gutierrez JA, Parikh N, Branch AD. Classical and emerging roles of vitamin D in hepatitis C virus infection. Semin Liver Dis. 2011;31(4):387–98.PubMedPubMedCentralCrossRefGoogle Scholar
  122. 122.
    García-Álvarez M, Pineda-Tenor D, Jiménez-Sousa MA, Fernández-Rodríguez A, Guzmán-Fulgencio M, Resino S. Relationship of vitamin D status with advanced liver fibrosis and response to hepatitis C virus therapy: a meta-analysis. Hepatology. 2014;60(5):1541–50.PubMedCrossRefGoogle Scholar
  123. 123.
    Luo YQ, Wu XX, Ling ZX, Cheng YW, Yuan L, Xiang C. Association between serum vitamin D and severity of liver fibrosis in chronic hepatitis C patients: a systematic meta-analysis. J Zhejiang Univ Sci B. 2014;15(10):900–6.PubMedPubMedCentralCrossRefGoogle Scholar
  124. 124.
    Villar LM, Del Campo JA, Ranchal I, Lampe E, Romero-Gomez M. Association between vitamin D and hepatitis C virus infection: a meta-analysis. World J Gastroenterol. 2013;19(35):5917–24.PubMedPubMedCentralCrossRefGoogle Scholar
  125. 125.
    Kitson MT, Sarrazin C, Toniutto P, Eslick GD, Roberts SK. Vitamin D level and sustained virologic response to interferon-based antiviral therapy in chronic hepatitis C: a systematic review and meta-analysis. J Hepatol. 2014;61(6):1247–52.PubMedCrossRefGoogle Scholar
  126. 126.
    Bitetto D, Fabris C, Fornasiere E, Pipan C, Fumolo E, Cussigh A, et al. Vitamin D supplementation improves response to antiviral treatment for recurrent hepatitis C. Transpl Int. 2011;24(1):43–50.PubMedCrossRefGoogle Scholar
  127. 127.
    Yokoyama S, Takahashi S, Kawakami Y, Hayes CN, Kohno H, Kohno H, et al. Effect of vitamin D supplementation on pegylated interferon/ribavirin therapy for chronic hepatitis C genotype 1b: a randomized controlled trial. J Viral Hepat. 2014;21(5):348–56.PubMedCrossRefGoogle Scholar
  128. 128.
    Esmat G, El Raziky M, Elsharkawy A, Sabry D, Hassany M, Ahmed A, et al. Impact of vitamin D supplementation on sustained virological response in chronic hepatitis C genotype 4 patients treated by pegylated interferon/ribavirin. J Interferon Cytokine Res. 2015;35(1):49–54.PubMedCrossRefGoogle Scholar
  129. 129.
    Abu-Mouch S, Fireman Z, Jarchovsky J, Zeina A-R, Assy N. Vitamin D supplementation improves sustained virologic response in chronic hepatitis C (genotype 1)-naïve patients. World J Gastroenterol. 2011;17(47):5184–90.PubMedPubMedCentralCrossRefGoogle Scholar
  130. 130.
    Terrier B, Lapidus N, Pol S, Serfaty L, Ratziu V, Asselah T, et al. Vitamin D in addition to peg-interferon-alpha/ribavirin in chronic hepatitis C virus infection: ANRS-HC25-VITAVIC study. World J Gastroenterol. 2015;21(18):5647–53.PubMedPubMedCentralCrossRefGoogle Scholar
  131. 131.
    Atsukawa M, Tsubota A, Shimada N, Yoshizawa K, Abe H, Asano T, et al. Effect of native vitamin D3 supplementation on refractory chronic hepatitis C patients in simeprevir with pegylated interferon/ribavirin. Hepatol Res. 2016;46(5):450–8.PubMedCrossRefGoogle Scholar
  132. 132.
    Nimer A, Mouch A, Vitamin D. improves viral response in hepatitis C genotype 2-3 naïve patients. World J Gastroenterol. 2012;18(8):800–5.PubMedPubMedCentralCrossRefGoogle Scholar
  133. 133.
    Thein HH, Yi Q, Dore GJ, Krahn MD. Natural history of hepatitis C virus infection in HIV-infected individuals and the impact of HIV in the era of highly active antiretroviral therapy: a meta-analysis. AIDS. 2008;22(15):1979–91.PubMedCrossRefGoogle Scholar
  134. 134.
    Graham CS, Baden LR, Yu E, Mrus JM, Carnie J, Heeren T, et al. Influence of human immunodeficiency virus infection on the course of hepatitis C virus infection: a meta-analysis. Clin Infect Dis. 2001;33(4):562–9.PubMedCrossRefGoogle Scholar
  135. 135.
    Torriani FJ, Rodriguez-Torres M, Rockstroh JK, Lissen E, Gonzalez-García J, Lazzarin A, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. New Engl J Med. 2004;351(5):438–50.PubMedCrossRefGoogle Scholar
  136. 136.
    Amrein K. Vitamin D status in critical care: contributor or marker of poor health? Lung India. 2014;31(3):299–300.PubMedPubMedCentralGoogle Scholar
  137. 137.
    Hewison M. Antibacterial effects of vitamin D. Nat Rev Endocrinol. 2011;7(6):337–45.PubMedCrossRefGoogle Scholar
  138. 138.
    Davies PD, Martineau AR. Vitamin D and tuberculosis: more effective in prevention than treatment? Int J Tuberc Lung Dis. 2015;19(8):876–7.PubMedCrossRefGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Department of Infectious DiseasesAarhus University HospitalAarhus NDenmark
  2. 2.Center for Global Health, Dept of Public HealthAarhus UniversityAarhus NDenmark

Personalised recommendations